Why this seasoned money manager sees real upside for this innovative B2B tech startup. on 10/26/2021. Learn More

BELLUS Health Inc.


Change: Change(%):
Volume: Open:
High: Low:
52Wk High: 52Wk Low:

BELLUS Health Inc. is a drug development company focused on rare diseases. Based in Laval, Quebec, the company has a portfolio of rare disease projects including KIACTA for AA amyloidosis (an orphan indication resulting in renal dysfunction that often rapidly leads to dialysis and death), clinical-stage Shigamab for Shiga toxin-producing Escherichia coli-related hemolytic uremic syndrome, and a research-stage project for AL amyloidosis. Its lead program, KIACTA, is partnered with global private equity firm Auven Therapeutics LLLP and is currently in phase 3 confirmation study.